Monday, May 23, 2022
  • PRESS RELEASE
  • ADVERTISE
  • CONTACT
Asia Post
No Result
View All Result
  • HOME
  • NEWS
    • INDIA
    • CHINA
    • WORLD
  • DEFENSE
  • POLITICS
  • BUSINESS
  • HEALTH
  • SPORTS
  • ENTRTAINMENT
  • TECHNOLOGY
  • LIFESTYLE
  • TRAVEL
  • OUR TEAM
Asia Post
No Result
View All Result

Russian vaccine proves best in protection against COVID-related mortality, shows study

January 17, 2022
in INDIA
0 0
0
Share on FacebookShare on TwitterShare on Email


The vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, is based on a safe and tested human adenovirus vector platform

Sputnik V: Russian vaccine proves best in protection against COVID-related mortality, shows study

Russia’s Sputnik V vaccine. RDIF

The world is gradually getting back on its feet after the long haul brought forth due to the coronavirus. However, the danger hasn’t lifted entirely.

While people around are getting vaccinated (some with the first dose and others fully vaccinated), news of new variants being recognised is also coming through. Several countries have imposed travel restrictions as World Health Organisation (WHO) designated a new coronavirus strain detected in South Africa as a “variant of concern”.

It is likely to take weeks to determine how effective current COVID-19 vaccines are against the variant.

This only goes to show that we need to continue being on high alert and get vaccinated, if not done yet. The news of new variant, on one hand raises concern but also reinstates belief in the power of vaccines.

Russia’s Sputnik V, world’s first registered vaccine based on a well-studied human adenoviral vector-based platform, was recently part of new studies to check on its efficacy. The vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, is based on a safe and tested human adenovirus vector platform.

Sputnik V is a two-vector vaccine against coronavirus. Also known as Gam-COVID-Vac, the vaccine uses a heterologous recombinant adenovirus approach using adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors for the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

The use of two varying serotypes, which are given 21 days apart, is intended to overcome any pre-existing adenovirus immunity in the population. Among the major COVID vaccines in development to date, only Gam-COVID-Vac uses this approach.

The technological platform of adenovirus-based vectors makes it easier and faster to create new vaccines through modifying the initial carrier vector with genetic material from new emerging viruses that helps to create new vaccines in relatively short time. Such vaccines provoke a strong response from a human immune system. Human adenoviruses are considered as some of the easiest to engineer in this way and therefore they have become very popular as vectors.

A unique independent nationwide observational study in EU member state Hungary estimating and directly comparing efficacy of five vaccines against COVID has demonstrated that the Russian Sputnik V vaccine has the highest (98 per cent) efficacy in preventing COVID-related mortality and 85.7 per cent efficacy against coronavirus infection leading alongside the vaccine by Moderna.

The Russian vaccine proved the best in protection against COVID related mortality and leads alongside the vaccine by Moderna in efficacy rate against COVID infection based on analysis of data from 820,000 individuals vaccinated with Sputnik V. The study has also demonstrated Sputnik V is 100 per cent effective against COVID related deaths in individuals aged 16–44 years.

Moreover, according to Ministry of Health of the Republic of San Marino on the Russian Sputnik V vaccine demonstrating it is 80 per cent effective against coronavirus infection from 6th to 8th months after administering the second dose. Efficacy of Sputnik V on 6-8 months is much higher than officially published efficacy of mRNA vaccines.

It can be established that adenoviral vaccines provide for longer efficacy than mRNA vaccines due to longer antibody and T-cell response. The data is based on the number of COVID infections in San Marino in November 2021. Efficacy was calculated based on data obtained from over 18,600 individuals fully vaccinated with Sputnik V not less than five months before November.

This clearly demonstrates that development stage of each vaccine is critical and more efforts are required for preventing any future strains from having the deadly impact that coronavirus has had in the recent past.

Dr Gajendra Singh is a public health expert. Dr Anuja Gupta is a microbiologist



Source link

Tags: COVIDrelatedmortalityprotectionprovesRussianshowsStudyvaccine
ShareTweetSend

Related Posts

INDIA

Construction Pace For Four, Six, Eight-Lane NHs Has Increased in Seven Years

May 23, 2022
INDIA

Stalin launches Kalaignarin All Village Integrated Agriculture Development Programme

May 23, 2022
INDIA

Man fatally shot on New York City subway in latest random attack

May 23, 2022
INDIA

Will Maharashtra witness a fourth wave of COVID-19? Minister clarifies

May 23, 2022
INDIA

Kiara Advani-Sidharth Malhotra kiss and make up: ‘Bhool ho gayi. We can’t stay without each other’- Exclusive! | Hindi Movie News

May 23, 2022
INDIA

ASHA workers at forefront of ensuring healthy India: PM Modi

May 23, 2022
Load More
Next Post

Drone attack at Abu Dhabi's new airport: 2 Indians among 3 killed in UAE; Yemen's Houthis claim responsibility

Hospital chains set for strong revenue, margin growth in FY22, Health News, ET HealthWorld

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Trending
  • Comments
  • Latest

India’s first case of Omicron subvariant BA.4 detected in Hyderabad

May 19, 2022

A Q&A with SEC Commissioner Hester Peirce, on her criticisms of the SEC's approach to crypto, chair Gary Gensler's leadership, being called "Crypto Mom", more (Benjamin Pimentel/Protocol)

May 14, 2022

Insect protein startup raises $30 million investment | China Breaking News | Top Stories | Political | Business | Entertainment

May 16, 2022

Outcry in Shanghai as person declared dead and put in body bag found to be alive | China

May 3, 2022

Man Declared Dead at Shanghai’s Elderly Care Centre, Found Alive in Morgue

May 2, 2022

Shanghai Tightens Lockdown Despite Falling COVID Cases

May 9, 2022

‘No end in sight’: Shanghai residents chafe at harsh Covid measures | China

May 10, 2022

Tesla vehicles roll off production line in Shanghai factory, local official says · TechNode

May 9, 2022

Why Quad Must Address the Elephant in the Room – Security Threat Looming over Taiwan

May 23, 2022

Construction Pace For Four, Six, Eight-Lane NHs Has Increased in Seven Years

May 23, 2022

US would defend Taiwan if attacked by China, says Joe Biden | Taiwan

May 23, 2022

China to include outstanding veterans and their stories in local chronicles

May 23, 2022

Stalin launches Kalaignarin All Village Integrated Agriculture Development Programme

May 23, 2022

Karan Kundrra blames Tejasswi Prakash for delaying their wedding, says ‘Madam ke pass time kahan hai’ | People News

May 23, 2022

Joe Biden calms concerns about Monkeypox, says ‘doesn’t rise to level of COVID19’

May 23, 2022

Man fatally shot on New York City subway in latest random attack

May 23, 2022
Asia Post

Get the latest news and follow the coverage of breaking news, local news, national, politics, and more from the Asia's top trusted sources.

Categories

  • BUSINESS
  • CHINA
  • DEFENSE
  • ENTRTAINMENT
  • HEALTH
  • INDIA
  • INDIA-NORTHEAST
  • LIFESTYLE
  • POLITICS
  • SPORTS
  • TECHNOLOGY
  • TRAVEL
  • WORLD

Recent News

  • Why Quad Must Address the Elephant in the Room – Security Threat Looming over Taiwan
  • Construction Pace For Four, Six, Eight-Lane NHs Has Increased in Seven Years
  • US would defend Taiwan if attacked by China, says Joe Biden | Taiwan
  • Home
  • Disclaimer
  • DMCA
  • Privacy Policy
  • Cookie Privacy Policy
  • Terms and Conditions
  • Our Team
  • Contact

Copyright © 2021 Asia Post.
Asia Post is not responsible for the content of external sites.

No Result
View All Result
  • HOME
  • NEWS
    • INDIA
    • CHINA
    • WORLD
  • DEFENSE
  • POLITICS
  • BUSINESS
  • HEALTH
  • SPORTS
  • ENTRTAINMENT
  • TECHNOLOGY
  • LIFESTYLE
  • TRAVEL
  • OUR TEAM

Copyright © 2021 Asia Post.
Asia Post is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In